CoChat

Management and potentialities of primary cancer cultures in preclinical and translational studies

Open access
Miserocchi, Giacomo, Mercatali, Laura, Liverani, Chiara, De Vita, Alessandro, Spadazzi, Chiara, Pieri, Federica, Bongiovanni, Alberto, Recine, Federica, Amadori, Dino, Ibrahim, Toni · 2017 · Journal of Translational Medicine
Cited by 123

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

The use of patient-derived primary cell cultures in cancer preclinical assays has increased in recent years. The management of resected tumor tissue remains complex and a number of parameters must be respected to obtain complete sample digestion and optimal vitality yield. We provide an overview of the benefits of correct primary cell culture management using different preclinical methodologies, and describe the pros and cons of this model with respect to other kinds of samples. One important advantage is that the heterogeneity of the cell populations composing a primary culture partially reproduces the tumor microenvironment and crosstalk between malignant and healthy cells, neither of which is possible with cell lines. Moreover, the use of patient-derived specimens in innovative preclinical technologies, such as 3D systems or bioreactors, represents an important opportunity to improve the translational value of the results obtained. In vivo models could further our understanding of the crosstalk between tumor and other tissues as they enable us to observe the systemic and biological interactions of a complete organism. Although engineered mice are the most common model used in this setting, the zebrafish (Danio rerio) species has recently been recognized as an innovative experimental system. In fact, the transparent body and incomplete immune system of zebrafish embryos are especially useful for evaluating patient-derived tumor tissue interactions in healthy hosts. In conclusion, ex vivo systems represent an important tool for cancer research, but samples require correct manipulation to maximize their translational value.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12967-017-1328-z

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 123

Metadata

Authors
Miserocchi, G., Mercatali, L., Liverani, C., De Vita, A., Spadazzi, C., Pieri, F., Bongiovanni, A., Recine, F., Amadori, D., & Ibrahim, T.
Venue
Journal of Translational Medicine
Published
2017-11-07
Volume
15
Issue
1
Pages
229-229
ISSN
1479-5876 (ISSN-L)
OpenAlex
W2767274043
Cited by
123
References
27
FWCI
2.05
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management and potentialities of primary cancer cultures in preclinical and translational studies. https://app.cochat.ai/papers/10.1186/s12967-017-1328-z
The paper
Miserocchi, G., Mercatali, L., Liverani, C., De Vita, A., Spadazzi, C., Pieri, F., Bongiovanni, A., Recine, F., Amadori, D., & Ibrahim, T. (2017). Management and potentialities of primary cancer cultures in preclinical and translational studies. Journal of Translational Medicine. https://doi.org/10.1186/s12967-017-1328-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.